TGFB1 and pancreatic neoplasm: The antifibrotic effect of losartan was associated with reduced number of activated TAFs and therefore decreased expression of downstream profibrotic factors, such as connective tissue growth factor (CTGF), TGF-β1, and ET-1 (Chauhan et al., 2013), which led to an ongoing clinical trial of losartan combined with chemotherapy in pancreatic tumors (NCT01821729).